World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology
- PMID: 34041027
- PMCID: PMC8142853
- DOI: 10.3389/fonc.2021.659800
World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology
Abstract
Significant advances in our understanding of the molecular genetics of pediatric and adult brain tumors and the resulting rapid expansion of clinical molecular neuropathology have led to improvements in diagnostic accuracy and identified new targets for therapy. Moreover, there have been major improvements in all facets of clinical care, including imaging, surgery, radiation and supportive care. In selected cohorts of patients, targeted and immunotherapies have resulted in improved patient outcomes. Furthermore, adaptations to clinical trial design have facilitated our study of new agents and other therapeutic innovations. However, considerable work remains to be done towards extending survival for all patients with primary brain tumors, especially children and adults with diffuse midline gliomas harboring Histone H3 K27 mutations and adults with isocitrate dehydrogenase (IDH) wild-type, O6 guanine DNA-methyltransferase gene (MGMT) promoter unmethylated high grade gliomas. In addition to improvements in therapy and care, access to the advances in technology, such as particle radiation or biologic therapy, neuroimaging and molecular diagnostics in both developing and developed countries is needed to improve the outcome of patients with brain tumors.
Keywords: neuro-oncology; neurology; neurosurgical oncology; oncology; pediatrics.
Copyright © 2021 Sulman and Eisenstat.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.J Neurosurg. 2018 Apr;128(4):1102-1114. doi: 10.3171/2016.11.JNS16973. Epub 2017 Jun 16. J Neurosurg. 2018. PMID: 28621624
-
Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patients.Ann Transl Med. 2019 Oct;7(20):541. doi: 10.21037/atm.2019.09.126. Ann Transl Med. 2019. PMID: 31807523 Free PMC article.
-
Characteristics of H3 K27M-mutant gliomas in adults.Neuro Oncol. 2017 Aug 1;19(8):1127-1134. doi: 10.1093/neuonc/now274. Neuro Oncol. 2017. PMID: 28201752 Free PMC article.
-
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.Neuro Oncol. 2012 Sep;14 Suppl 4(Suppl 4):iv100-8. doi: 10.1093/neuonc/nos206. Neuro Oncol. 2012. PMID: 23095825 Free PMC article. Review.
-
Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.J Neurooncol. 2022 Jul;158(3):369-378. doi: 10.1007/s11060-022-04024-5. Epub 2022 May 14. J Neurooncol. 2022. PMID: 35567713 Review.
Cited by
-
ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.Cancer Res. 2023 May 5;83(14):2421-37. doi: 10.1158/0008-5472.CAN-23-0186. Online ahead of print. Cancer Res. 2023. PMID: 37145169 Free PMC article.
-
Pediatric neurosurgical-oncology scope and management paradigms in Sub-Saharan Africa: a collaboration among 7 referral hospitals on the subcontinent.Front Oncol. 2023 Nov 1;13:1257099. doi: 10.3389/fonc.2023.1257099. eCollection 2023. Front Oncol. 2023. PMID: 38023182 Free PMC article.
-
The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.Neuro Oncol. 2022 Sep 1;24(9):1408-1422. doi: 10.1093/neuonc/noac117. Neuro Oncol. 2022. PMID: 35481923 Free PMC article.
-
BMP2 and BMP7 cooperate with H3.3K27M to promote quiescence and invasiveness in pediatric diffuse midline gliomas.Elife. 2024 Oct 7;12:RP91313. doi: 10.7554/eLife.91313. Elife. 2024. PMID: 39373720 Free PMC article.
-
Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies.Oncogene. 2022 Jan;41(4):461-475. doi: 10.1038/s41388-021-02102-y. Epub 2021 Nov 10. Oncogene. 2022. PMID: 34759345 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials